STAT+: In first big randomized trial, Abiomed’s heart pump reduced deaths in heart attack patients

STAT April 7, 2024
Lizzy Lawrence

A controversial heart pump from Abiomed reduced the number of deaths in severe heart attack patients, according to a highly anticipated randomized trial presented at the American College of Cardiology conference and published in the New England Journal of Medicine on Sunday.

The trial, which took 10 years to enroll, followed 355 patients for 180 days in Denmark, Germany, and the United Kingdom who came into the hospital with a heart attack and dangerously low blood flow, known as cardiogenic shock. Half...

Today's Sponsors

Today's Sponsor